title: Erythrocyte antigen and reticulocyte engraftment after allogeneic hematopoietic stem cell transplantation.
abstract: The aim of this study was to study the usefulness of erythrocyte antigen (EA) measurement to study engraftment after allogeneic HSCT. In all, 31 consecutive patients receiving HLA-identical bone marrow (BM) (n=13) or peripheral blood stem cells (n=18) were investigated. Apart from the ABO group, 15 EAs representing six minor blood groups were followed by the simple tube agglutination technique. A total of 20 (64.5%) patients received ABO-identical, eight (25.8%) received ABO minor and three (9.7%) received ABO major mismatched grafts. In all, 29 patients were followed for a median of 12 (6-16) months; 65% of the patients expressed donor type EA 1 month and almost all did so 6 months after transplant. Reticulocyte engraftment was significantly shorter than EA engraftment (median 18 vs 35 days) (P=0.001). Patients who received PB stem cells showed significantly faster EA and reticulocyte engraftment than patients who received BM stem cells (P=0.038 and 0.025). ABO compatibility did not have an impact on reticulocyte and EA engraftment (P=0.4 and 0.55). The earliest donor type EA detected was from the Rh and Kidd system. These data suggest that EA and reticulocyte assays are useful in monitoring engraftment.
authors.affiliation: Department of Hematology, Faculty of Medicine, Ankara University, Blood Bank and Apheresis Unit, Ankara, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Yildirim
authors.forename: Y
authors.initials: Y
authors.lastname: Ozer
authors.forename: M K
authors.initials: MK
authors.lastname: Yüksel
authors.forename: M
authors.initials: M
authors.lastname: Arat
authors.forename: O
authors.initials: O
authors.lastname: Arslan
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D000941:Antigens / Q000097:blood* / Q000627:therapeutic use; D001788:Blood Grouping and Crossmatching; D002292:Carcinoma, Renal Cell / Q000628:therapy; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D007938:Leukemia / Q000628:therapy; D008297:Male; D008875:Middle Aged; D017701:Reticulocyte Count; D012156:Reticulocytes / Q000637:transplantation*; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000941:Antigens